Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

BACH1 and HIF1 alpha predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC) (2021) Vladimirova V, Schneeweiss A, Jackisch C, Weber KE, Denkert C, Schmatloch S, Karn T, et al. Conference contribution Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto (2021) Labidi-Galy SI, Schneeweiss A, Sinn HP, Blohmer JU, Romanens L, Zahm DM, Huober J, et al. Conference contribution Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials (2021) Furlanetto J, Denkert C, Untch M, Sinn B, Lederer B, Schneeweiss A, Mueller V, et al. Conference contribution Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial (2021) Llop-Guevara A, Vladimirova V, Schneeweiss A, Villacampa G, Karn T, Zahm DM, Herencia-Ropero A, et al. Journal article, Original article Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2,-3, and-7 trials: Additional results and key subgroup findings (2021) Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir NS, Conejo EA, et al. Conference contribution Epigenetic regulation of the putative breast cancer metastasis suppressor gene SCN4B (2021) Hilgers L, Hartmann A, Fasching P, Villwock S, Moll L, Roger S, Knuechel-Clarke R, et al. Conference contribution Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from pd-l1 inhibition in women with early triple-negative breast cancer (2021) Sinn BV, Loibl S, Hanusch CA, Zahm DM, Sinn HP, Untch M, Weber K, et al. Journal article Associations between genetically predicted circulating protein concentrations and endometrial cancer risk (2021) Zhu J, O’mara TA, Liu D, Setiawan VW, Glubb D, Spurdle AB, Fasching P, et al. Journal article Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials (2021) Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, et al. Journal article Update Breast Cancer 2020 Part 5 - Moving Therapies from Advanced to Early Breast Cancer Patients (2021) Lux MP, Schneeweiss A, Hartkopf AD, Müller V, Janni W, Belleville E, Stickeler E, et al. Journal article, Review article